| Literature DB >> 29562670 |
Abstract
The aim of this study is the application of a software tool to the design of stripping columns to calculate the removal of trihalomethanes (THMs) from drinking water. The tool also allows calculating the rough capital cost of the column and the decrease in carcinogenic risk indeces associated with the elimination of THMs and, thus, the investment to save a human life. The design of stripping columns includes the determination, among other factors, of the height (HOG), the theoretical number of plates (NOG), and the section (S) of the columns based on the study of pressure drop. These results have been compared with THM stripping literature values, showing that simulation is sufficiently conservative. Three case studies were chosen to apply the developed software. The first case study was representative of small-scale application to a community in Córdoba (Spain) where chloroform is predominant and has a low concentration. The second case study was of an intermediate scale in a region in Venezuela, and the third case study was representative of large-scale treatment of water in the Barcelona metropolitan region (Spain). Results showed that case studies with larger scale and higher initial risk offer the best capital investment to decrease the risk.Entities:
Keywords: disinfection by-products; drinking water; human health risk assessment; stripping columns; trihalomethanes (THMs); water technology design
Year: 2018 PMID: 29562670 PMCID: PMC5874791 DOI: 10.3390/toxics6010018
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Input parameters to determine the exposure of THMs through the three pathways.
| Parameter | Value | Reference |
|---|---|---|
| 365 | [ | |
| 29 | [ | |
| 60.55 | [ | |
| 70 | [ | |
| IRwater, Water ingestion rate (L·day−1) | 2 | [ |
| SA, Skin surface area (cm2) | 17,200 | [ |
| Skin in contact with water (%) | 80 | [ |
| ET, Exposure time (h·day−1) | 0.315 | [ |
| IRair, Inhalation rate (m3·h−1) | 0.75 | [ |
| ABS, Absorption eff. in alveoli (%) | 50 | [ |
Table 2 compiles the specific properties of the contaminants for HHRA.
Specific properties and SF values of THMs for HHRA [23].
| CHCl3 | CHBrCl2 | CHBr2Cl | CHBr3 | |
|---|---|---|---|---|
| Permeability coeff. (cm·h−1) | 8.9·10−3 | 5.8·10−3 | 3.9·10−3 | 2.6·10−3 |
| SF Oral (kg·day·mg−1) | 3.10·10−2 | 6.20·10−2 | 8.40·10−2 | 7.90·10−2 |
| SF Dermal (kg·day·mg−1) | 3.10·10−2 | 6.20·10−2 | 8.40·10−2 | 7.90·10−2 |
| SF Inhalation (kg·day·mg−1) | 8.05·10−2 | 1.29·10−1 | 8.40·10−2 | 3.85·10−2 |
General information of the case studies.
| Case Study 1 | Case Study 2 | Case Study 3 | |
|---|---|---|---|
| Reference | [ | [ | [ |
| Location | Córdoba (ES) | San Diego (VE) | Sant Joan Despí (ES) |
| Treatment capacity, | 1260 | 15,000 | 330,000 |
| 3000 | 120,000 | 2,250,000 | |
| 22.0 | 70.0 | 9.4 | |
| - | 10.0 | 18.7 | |
| - | 2.0 | 28.8 | |
| - | - | 39.6 | |
| Input Total (µg·L−1) | 22.0 | 82.0 | 96.5 |
| Output Total (µg·L−1) | 10.0 | 21.0 | 21.7 |
| % THMs Removed | 54.6 | 74.4 | 77.6 |
Parameters for stripping columns from case study simulations.
| Outputs | Case 1 | Case 2 | Case 3 |
|---|---|---|---|
| Number of columns, | 1 | 1 | 14 |
| 3.7 × 10−3 | 3.5 × 10−3 | 1.5 × 10−3 | |
| 5.9 | 6.2 | 14.7 | |
| Gas flow, | 7457 | 93,502 | 345,691 |
| Filling type | Hiflow ring | Hiflow ring | Envipac ring |
| 103 | 103 | 95 | |
| 1.08 × 10−3 | 1.08 × 10−3 | 4.59 × 10−4 | |
| 119 | 119 | 96 | |
| Section, | 0.20 | 2.35 | 6.72 |
| Pressure drop (mm Hg·m−1) | 25.5 | 25.5 | 4.0 |
| 3.91 | 3.88 | 3.71 | |
| P top (atm) | 3.95 × 10−7 | 1.88 × 10−6 | 5.92 × 10−7 |
| 1.42 | 3.59 | 4.70 | |
| 5.55 | 13.95 | 17.43 |
Parameters for stripping columns from references.
| Reference | [ | [ | [ | [ | [ | [ |
|---|---|---|---|---|---|---|
| Input data | ||||||
| Sample | CHCl3 | CHCl3 | CHCl3 | THMs | THMs | THMs |
| Input total (µg·L−1) | 536. 638 | 2000 | 50–300 | 29–40 | 15.8 | 165.5 |
| % THMs removed | 97.5 > 99.9 | 55–90 | 55–87 | 45–82 | 71–85 | 23–51 |
| 4 | 1.05 | 0.9 | 1. 2.1. 2.5 | 2.4 | 2.4 | |
| Section, | 0.270 | 0.066 | 0.049 | 0.018 | 2.000 | 0.300 |
| 6700–9680 | 2376 | 40 | nr | 147,000 | 4200 | |
| 1800–2600 | nr | 13–40 | 10–40 | 22 | 38 | |
| Calculated output data | ||||||
| 1.4–2.2 × 10−2 | nr | 0.14–0.73 | 0.35–1.22 | 0.68 | 0.15 | |
| 185–296 | nr | 1.2–6.5 | 1.8–6.0 | 3.6 | 16.1 | |
| 134–194 | 59–334 * | 125–662 | - | 10,227 | 869 | |
nr, non-reported, * reported values.
Risk, capital investment, and cost to saved lives ratio.
| Outputs | Case 1 | Case 2 | Case 3 |
|---|---|---|---|
| Initial risk | 2.60 × 10−5 | 1.04 × 10−4 | 1.48 × 10−4 |
| Final risk | 1.18 × 10−5 | 2.65 × 10−5 | 3.32 × 10−5 |
| Cancer deaths avoided (lifes) | 0.043 | 9.3 | 258.3 |
| Capital investment, | 216,114 | 2,118,552 | 38,899,070 |
| Ratio cost-life (Eu·life−1) | 5,073,100 | 227,801 | 150,596 |